Silexion Therapeutics Reports Positive Data for SIL204

The latest announcement is out from Silexion Therapeutics ( (SLXN) ).

On March 5, 2025, Silexion Therapeutics announced positive initial data from the systemic administration of SIL204 in orthotopic pancreatic cancer models. The data demonstrated SIL204’s efficacy in reducing both primary tumor growth and metastatic spread, marking a significant advancement in their development program. The findings validate SIL204’s effectiveness in a clinically relevant setting and suggest potential for treating both primary and metastatic pancreatic cancer with a minimally-invasive delivery method. Silexion is exploring an expanded development plan for SIL204 based on these results.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, which are common oncogenic drivers in human cancers. The company is advancing its siRNA candidate, SIL204, and has shown promising results in preclinical studies, particularly for non-resectable pancreatic cancer.

YTD Price Performance: -44.22%

Average Trading Volume: 13,282,906

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $9.34M

For an in-depth examination of SLXN stock, go to TipRanks’ Stock Analysis page.